Argent BioPharma exits LSE, focuses on ASX listing

Argent BioPharma (ASX:RGT), a company in the biopharmaceutical sector, has announced its decision to delist from the London Stock Exchange.

The company plans to retain its listing on the Australian Securities Exchange.

Following an in-depth review of listing requirements and associated costs, Argent BioPharma has decided to request the cancellation of its ordinary shares from the secondary international commercial companies listing on the LSE.

The delisting is expected to take effect from Dec. 31.

Shareholder approval is not required for the delisting due to the current listing category.

Roby Zomer, CEO and Managing Director of Argent BioPharma, commented, “This decision will streamline our operations and enhance administrative efficiency.”

The announcement comes as part of the company's ongoing strategy to simplify its listing status and increase operational efficiency.

Shareholders with queries about the delisting are encouraged to contact their investment advisers.

Argent BioPharma will provide updates to holders of its depositary interests concerning the future tradability of its securities.

Argent BioPharma's main operations remain based in the EU, with a growing investor base in the United States, where potential future dual listing options are being explored.

At the time of reporting, Argent Biopharma's share price was $0.25.